Iza-Bren Yields Statistically Significant Efficacy in Advanced TNBC
Statistically significant and clinically meaningful improvements in progression‑free survival (PFS) and overall survival (OS) were noted with izalontamab brengitecan (iza‑bren) for patients with unresectable locally advanced or metastatic triple‑negative breast cancer with disease progression after prior taxane therapy, according to a press release from Bristol Myers Squibb.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management